Processa Acquires Vidya Therapeutics for $200M to Develop BTK Inhibitor Pipeline
Processa Pharmaceuticals has acquired clinical-stage biotech company Vidya Therapeutics, gaining access to its lead asset VT-7208, a next-generation Bruton's tyrosine kinase (BTK) inhibitor. The acquisition is part of a broader strategy that includes securing $200 million in private financing from healthcare-focused institutional investors. The funds will support parallel Phase 2 development programs for VT-7208 across three immune-mediated diseases: food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS). The company plans to initiate trials by the end of 2026 and expects proof-of-concept data between late 2027 and mid-2028. This move significantly shifts Processa's focus toward immunology and neurology, with a broader pipeline. However, existing shareholders will be diluted substantially post-transaction, owning only about 0.9% of the combined company on a fully diluted basis. Despite this dilution risk, management anticipates that available cash from financing should support operations through mid-2029.
Tickers: $PRCT
Topics: Biotechnology BTK Inhibitors Clinical Trials Pharmaceuticals